

# Lorraine V Kalia

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6885550/lorraine-v-kalia-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

6,774

citations

27

h-index

65

g-index

65

ext. papers

8,174

ext. citations

8.6

avg, IF

6.7

L-index

#	Paper	IF	Citations
62	Small molecule inhibitors of $\beta$ -Synuclein oligomers identified by targeting early dopamine-mediated motor impairment in <i>C. elegans</i> . <i>Molecular Neurodegeneration</i> , <b>2021</b> , 16, 77	19	2
61	Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. <i>Neurology: Genetics</i> , <b>2021</b> , 7, e600	3.8	1
60	Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 1772-1780	7	8
59	C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. <i>Current Neuropharmacology</i> , <b>2021</b> , 19, 1038-1068	7.6	3
58	Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 201-209	2.6	1
57	Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members. <i>Neural Regeneration Research</i> , <b>2021</b> , 16, 684-685	4.5	4
56	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , <b>2021</b> , 1-5	1	0
55	COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 3-8	5.3	10
54	Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis. <i>Journal of Visualized Experiments</i> , <b>2021</b> ,	1.6	1
53	An Intelligent Diagnosis: SMART Syndrome. <i>American Journal of Medicine</i> , <b>2021</b> , 134, 863-865	2.4	
52	The eIF2 $\alpha$ kinase HRI triggers the autophagic clearance of cytosolic protein aggregates. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 296, 100050	5.4	9
51	Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 864-872	2.6	5
50	LRRK2 and $\beta$ -Synuclein: Distinct or Synergistic Players in Parkinson's Disease?. <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 577	5.1	23
49	Deep Brain Stimulation of the Medial Septal Nucleus Induces Expression of a Virally Delivered Reporter Gene in Dentate Gyrus. <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 463	5.1	1
48	Methods for detecting toxic $\beta$ -Synuclein species as a biomarker for Parkinson's disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2020</b> , 57, 291-307	9.4	6
47	Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by $\beta$ -Synuclein. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 17	7.3	27
46	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. <i>Neurology</i> , <b>2020</b> , 94, 481-494	6.5	60

45	Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson's disease. <i>Journal of Neurosurgery</i> , <b>2020</b> , 1-6	3.2	4
44	Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease". <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 74, 78-79	3.6	3
43	BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. <i>Frontiers in Cell and Developmental Biology</i> , <b>2020</b> , 8, 716	5.7	0
42	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 65, 165-171	3.6	5
41	Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 907	9.8	17
40	Diagnostic biomarkers for Parkinson's disease: focus on $\beta$ synuclein in cerebrospinal fluid. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 59, 21-25	3.6	10
39	Deep brain stimulation: potential for neuroprotection. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 174-185	5.3	30
38	Is there a role for MR-guided focused ultrasound in Parkinson's disease?. <i>Movement Disorders</i> , <b>2018</b> , 33, 575-579	7	4
37	Emerging disease-modifying strategies targeting $\beta$ synuclein for the treatment of Parkinson's disease. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 3080-3089	8.6	10
36	Biomarkers for cognitive dysfunction in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 46 Suppl 1, S19-S23	3.6	27
35	[F]AV-1451 binding and postmortem pathology of CBD. <i>Movement Disorders</i> , <b>2018</b> , 33, 1360-1361	7	4
34	Parkinsonism due to A53E $\beta$ synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. <i>Movement Disorders</i> , <b>2018</b> , 33, 1950-1955	7	12
33	Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes. <i>Movement Disorders</i> , <b>2017</b> , 32, 106	7	
32	$\beta$ Synuclein and Parkinsonism: Updates and Future Perspectives. <i>Current Neurology and Neuroscience Reports</i> , <b>2017</b> , 17, 31	6.6	46
31	Complex genomic rearrangement in SPG11 due to a DNA replication-based mechanism. <i>Movement Disorders</i> , <b>2017</b> , 32, 1792-1794	7	1
30	Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. <i>Parkinson's Disease</i> , <b>2017</b> , 2017, 5015307	2.6	20
29	Animal models of $\beta$ synucleinopathy for Parkinson disease drug development. <i>Nature Reviews Neuroscience</i> , <b>2017</b> , 18, 515-529	13.5	120
28	$\beta$ Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , <b>2016</b> , 39, 750-762	13.3	92

27	Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , <b>2016</b> , 12, 65-6	15	113
26	Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2016</b> , 3, 15051	6.4	10
25	Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 407-12	3.6	17
24	Parkinson's disease. <i>Lancet, The</i> , <b>2015</b> , 386, 896-912	40	2652
23	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1442-50	7	146
22	βSynuclein and Lewy pathology in Parkinson's disease. <i>Current Opinion in Neurology</i> , <b>2015</b> , 28, 375-81	7.1	63
21	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 100-5	17.2	191
20	Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. <i>Neurotherapeutics</i> , <b>2014</b> , 11, 6-23	6.4	89
19	Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 2626-31	11.5	282
18	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , <b>2014</b> , 1, 76-78	2.2	5
17	Direct detection of alpha synuclein oligomers in vivo. <i>Acta Neuropathologica Communications</i> , <b>2013</b> , 1, 6	7.3	37
16	βSynuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , <b>2013</b> , 73, 155-69	9.4	209
15	Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. <i>Movement Disorders</i> , <b>2013</b> , 28, 131-44	7	84
14	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , <b>2012</b> , 78, 838-9	6.5	5
13	Ubiquitinylation of βsynuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). <i>PLoS ONE</i> , <b>2011</b> , 6, e14695	3.7	98
12	Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. <i>Nature Medicine</i> , <b>2011</b> , 17, 470-8	50.5	126
11	Thoracic myelopathy from coincident fluorosis and epidural lipomatosis. <i>Canadian Journal of Neurological Sciences</i> , <b>2010</b> , 37, 276-8	1	5
10	Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning. <i>PLoS Biology</i> , <b>2009</b> , 7, e41	9.7	134

9	NMDA receptors in clinical neurology: excitatory times ahead. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 742-55	24.1	333
8	PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex. <i>EMBO Journal</i> , <b>2006</b> , 25, 4971-82	13	51
7	Severity of chronic pain and its relationship to quality of life in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2005</b> , 11, 322-7	5	136
6	Src in synaptic transmission and plasticity. <i>Oncogene</i> , <b>2004</b> , 23, 8007-16	9.2	130
5	Src kinases: a hub for NMDA receptor regulation. <i>Nature Reviews Neuroscience</i> , <b>2004</b> , 5, 317-28	13.5	625
4	Differential frequency dependence of P2Y1- and P2Y2- mediated Ca <sup>2+</sup> signaling in astrocytes. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 4437-44	6.6	75
3	Glycine binding primes NMDA receptor internalization. <i>Nature</i> , <b>2003</b> , 422, 302-7	50.4	339
2	Interactions between Src family protein tyrosine kinases and PSD-95. <i>Neuropharmacology</i> , <b>2003</b> , 45, 720-35	35	82
1	Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. <i>Neuron</i> , <b>2002</b> , 34, 127-38	13.9	171